Physician profile
Mark H Knapp
NPI 1952359549
$67,170.81
in general payments reported to CMS, 2019-2025
58 companies · $8,370 in 2025
The $8,370 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,872 · 2020: $4,256 · 2021: $8,991 · 2022: $13K · 2023: $7,740 · 2024: $15K · 2025: $8,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Honoraria: $5,294 · Travel and Lodging: $2,653 · Food and Beverage: $2,446 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $14.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,838.00 |
| Honoraria | $5,294.00 |
| Travel and Lodging | $2,653.11 |
| Food and Beverage | $2,445.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $14.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $11,933.93 | 2020-2024 | Enhertu |
| Pharmacosmos Therapeutics INC. | $7,280.30 | 2024 | Monoferric |
| Rigel Pharmaceuticals, INC. | $5,841.93 | 2019-2022 | |
| Gilead Sciences, INC. | $5,808.36 | 2021-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $4,967.50 | 2020-2023 | Xpovio |
| Incyte Corporation | $4,966.39 | 2019-2025 | Jakafi |
| Jazz Pharmaceuticals INC. | $3,277.84 | 2022-2024 | |
| Kite Pharma, INC. | $3,055.44 | 2020-2024 | Yescarta |
| Glaxosmithkline, LLC. | $2,825.69 | 2020-2025 | Ojjaara |
| Beigene USA, INC. | $2,666.88 | 2020-2023 | Brukinsa |
| Blueprint Medicines Corporation | $2,520.00 | 2021-2024 | |
| Epizyme, INC. | $2,500.00 | 2020-2021 | |
| Seagen INC. | $1,798.29 | 2019-2022 | |
| Cti Biopharma Corp. | $1,456.92 | 2022 | |
| Caris Mpi, INC. | $1,044.20 | 2025 | Mi Cancer Seek |
Show all 55 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.